Abstract
Aspergillus fumigatus is the causative agent of aspergillosis, a frequently invasive colonization of the lungs of immuno-compromised patients. GNA1 (D-glucosamine-6-phosphate N-acetyltransferase) catalyses the acetylation of GlcN-6P (glucosamine-6-phosphate) to GlcNAc-6P (N-acetylglucosamine-6-phosphate), a key intermediate in the UDP-GlcNAc biosynthetic pathway. Gene disruption of gnal in yeast and Candida albicans has provided genetic validation of the enzyme as a potential target. An understanding of potential active site differences between the human and A. fumigatus enzymes is required to enable further work aimed at identifying selective inhibitors for the fungal enzyme. In the present study, we describe crystal structures of both human and A. fumigatus GNA1, as well as their kinetic characterization. The structures show significant differences in the sugar-binding site with, in particular, several non-conservative substitutions near the phosphate-binding pocket. Mutagenesis targeting these differences revealed drastic effects on steady-state kinetics, suggesting that the differences could be exploitable with small-molecule inhibitors.
Original language | English |
---|---|
Pages (from-to) | 217-223 |
Number of pages | 7 |
Journal | Biochemical Journal |
Volume | 415 |
DOIs | |
Publication status | Published - 15 Oct 2008 |
Keywords
- Aspergillus fumigatus
- Inhibitor design
- Kinetics
- Mutagenesis
- Protein structure
- UDP-GlcNAc biosynthesis
- X-ray crystallography
- Glucosamine-6-phosphate acetyltransferase
- Blastocladiella emersonii
- Hexosamine biosynthesis
- Invasive aspergillosis
- Cell wall
- Protein
- Acetylglucosamine
- Refinement
- Therapy
- Program